O fornecimento de um fármaco fabricado segundo as normas de BPFa apoia o primeiro estudo clínico em seres humanos do novo RNA autorreplicante (srRNA) RBI-4000 ALBANY, N.Y., Sept. 13, 2023
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research,
L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain du nouvel ARN auto-répliquant (ARNar) RBI-4000 ALBANY, ÉTAT DE NEW
ABU DHABI, United Arab Emirates, Sept. 13, 2023 (GLOBE NEWSWIRE) — Under its new identity as “AIM Congress,” the Organizing Committee of the World’s Leading Investment Platform will once again